Toggle Main Menu Toggle Search

Open Access padlockePrints

Cross-validated risk scores adaptive enrichment (CADEN) design

Lookup NU author(s): Dr Svetlana CherlinORCiD, Professor James WasonORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2024 The AuthorsWe propose a Cross-validated ADaptive ENrichment design (CADEN) in which a trial population is enriched with a subpopulation of patients who are predicted to benefit from the treatment more than an average patient (the sensitive group). This subpopulation is found using a risk score constructed from the baseline (potentially high-dimensional) information about patients. The design incorporates an early stopping rule for futility. Simulation studies are used to assess the properties of CADEN against the original (non-enrichment) cross-validated risk scores (CVRS) design which constructs a risk score at the end of the trial. We show that when there exists a sensitive group of patients, CADEN achieves a higher power and a reduction in the expected sample size compared to the CVRS design. We illustrate the application of the design in two real clinical trials. We conclude that the new design offers improved statistical efficiency over the existing non-enrichment method, as well as increased benefit to patients. The method has been implemented in an R package caden.


Publication metadata

Author(s): Cherlin S, Wason JMS

Publication type: Article

Publication status: Published

Journal: Contemporary Clinical Trials

Year: 2024

Volume: 144

Print publication date: 01/09/2024

Online publication date: 06/07/2024

Acceptance date: 03/07/2024

Date deposited: 22/07/2024

ISSN (print): 1551-7144

ISSN (electronic): 1559-2030

Publisher: Elsevier Inc.

URL: https://doi.org/10.1016/j.cct.2024.107620

DOI: 10.1016/j.cct.2024.107620

Data Access Statement: The software package is provided. The real data used in this article are publicly available.


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Medical Research Council
MR/S014357/1
MRC

Share